

National Board of Examinations

Question Paper Name :	DrNB Medical Oncology Paper1
Subject Name :	DrNB Medical Oncology Paper1
Creation Date :	2024-05-15 21:33:57
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB Medical Oncology Paper1

Group Number :	1
Group Id :	3271871968
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB Medical Oncology Paper1

Section Id :	3271871971
Section Number :	1
Section type :	Offline

Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271871975
Question Shuffling Allowed :	No
Is Section Default? :	null

Question Number : 1 Question Id : 32718725763 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Describe cell cycle. [2]
- b) List various cyclin dependent kinases inhibitors and their role in cell cycle progression. [3]
- c) Compare response rate, outcome and toxicity of various CDK inhibitors in breast cancer management. [5]

Question Number : 2 Question Id : 32718725764 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Imaging features of abdominal neuroblastoma and Wilms' tumour. [3]

- b) Image dependent risk factors in neuroblastoma. [2]
- c) Outline treatment for different stages of Wilms' tumour with 2 year survival for each stage. [5]

Question Number : 3 Question Id : 32718725765 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Define cancer cachexia. [2]
- b) Pathophysiology and cytokines involved in cancer cachexia. [4]
- c) List various treatment intervention strategies. [4]

Question Number : 4 Question Id : 32718725766 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Regarding chronic myeloid leukemia:

- a) Principle of RQ PCR (Real time reverse transcriptase quantitative polymerase chain reaction). [3]
- b) Concept and criteria to 'stop Imatinib'. [2]
- c) Compare mechanism and toxicity of Imatinib, Nilotinib and Dasatinib. [5]

Question Number : 5 Question Id : 32718725767 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Epidemiology of thyroid cancer in India. [3]
- b) TNM staging. [3]
- c) Algorithm for treatment of low risk thyroid cancer. [4]

Question Number : 6 Question Id : 32718725768 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Molecular biology of HER2/neu pathway. [3]
- b) FISH testing for HER2/neu : Indications and interpretation. [3]
- c) List various drugs and their toxicities acting on this pathway and various tumours expressing HER2/neu . [4]

Question Number : 7 Question Id : 32718725769 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Principles and methodology of ELISA. [4]
- b) List investigations for diagnosis of invasive aspergillosis. [2]
- c) Treatment of pulmonary aspergillosis in a case of acute myeloid leukemia. [4]

Question Number : 8 Question Id : 32718725770 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Endpoints for trials in palliative care setting. [5]
- b) Hyponatremia in Oncology setting. [5]

Question Number : 9 Question Id : 32718725771 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Molecular markers for gliomas and their significance. [4]
- b) Immunotherapy for brain tumors. [4]
- c) Temozolamide: dose and toxicity. [2]

Question Number : 10 Question Id : 32718725772 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Correct Marks : 10

- a) Biomarkers for immunotherapy response in Head and Neck cancer. [3]
- b) Adaptive radiation therapy for Head & Neck cancer. [3]
- c) Radiopharmaceuticals in Oncology. [4]